Paradigm Biopharmaceuticals (ASX:PAR) has activated a clinical site in Australia, with the first patient providing consent to participate in the phase three trial testing injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis pain, according to a Tuesday filing with the Australian bourse.
The trial also includes 48 US sites preparing for activation, with first patient consent and dosing expected next quarter, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。